Cost-Benefit Analysis of Capecitabine Versus 5-Fluorouracil/Leucovorin in the Treatment of Colorectal Cancer in the Netherlands

Clinical Therapeutics

Volumn 26, Issue 4, 2004, Pages 579-589

  Jansman, Frank G A ^a,b   Postma, Maarten J ^b   Van Hartskamp, David ^b   Willemse, Pax H B ^c   Brouwers, Jacobus R B J ^b  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Capecitabine; Colorectal cancer; Cost benefit analysis; Economics; Fluorouracil; Toxicity

Indexed keywords

AMPICILLIN; CAPECITABINE; CEFAZOLIN; CEFTAZIDIME; CEFTIZOXIME; DOMPERIDONE; FLUCLOXACILLIN; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; METOCLOPRAMIDE; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN;

ADULT; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DATA ANALYSIS; DAY CARE; DEHYDRATION; DIARRHEA; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH CENTER; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; NAUSEA; NETHERLANDS; NEUTROPENIA; OUTPATIENT; PALLIATIVE THERAPY; REVIEW; SIMULATION; STOMATITIS; TOXICITY; TRAVEL; VOMITING;

EID: 2342624007     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90060-4     Document Type: Article

References (23)

1. Van Cutsem E, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer. 2002;38:1429-1436.
2. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38:99-166.
3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939-944.
4. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000; 321:531-535.
5. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
6. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
7. Twelves C, Boyer M, Findlay M, et al, for the Xeloda Colorectal Cancer Study Group. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 2001;37:597-604.
8. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
9. Borner MM, Schöffski P, De Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349-358.
10. Giuliani G, Lucioni C, Mazzi S, et al. Economic evaluation of oral capecitabine vs intravenous 5-fluorouracil plus leucovorin (Mayo regimen) in the treatment of advanced colorectal cancer [in Italian]. PharmacoEconomics. 2002;4:31-38.
11. Omnes LF, Woronoff Lemsi MC, Foutel V. Pharmacoeconomic assessment of capecitabine oral chemotherapy versus FUFOL Mayo Clinic chemotherapy in the treatment of colorectal cancer. Value Health. 2003;6:733-734. Abstract.
12. Hieke K, Grothey A. Cost implications of oral treatment of colorectal cancer in Germany. Value Health. 2003;6:736. Abstract.
13. Jansman FG, Sleijfer DT, Coenen JL, et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf. 2000;23:255-278.
14. Riteco JA, De Heij LJM, Van Luijn JCF, et al. Guidelines for Pharmaco-Economic Research [in Dutch]. Amstelveen, the Netherlands: College Voor Zorgverzekeringen; 1999.
15. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, UK: Oxford University Press; 1997.
16. Oostenbrink JB, Koopmanschap MA, Rutten FF. Guide to Investigation of Costs [in Dutch]. Amstelveen, the Netherlands: College Voor Zorgverzekeringen; 2000.
17. Van Loenen AC. Formulary of the Dutch Foundation for Health Care Insurance [in Dutch]. Amstelveen, the Netherlands: College Voor Zorgverzekeringen; 2002.
18. Xeloda (Capecitabine). Summary of Product Characteristics. Hertfordshire, UK: Roche Registration Ltd; 2001.
19. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353-367.
20. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 1997;8:65-70.
21. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer. 2002;86:1677-1683.
22. Maroun J, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. PharmacoEconomics. 2003;21:1039-1051.
23. Groot MT, Vanoverbeke N, Annemans L, Uyl-de Groot CA. Comparing costs of two treatments. Metastatic colorectal carcinoma [in Dutch]. Pharmaceutisch Weekblad. 2002;137:714-721.